Continuous insulin infusion in hyperglycaemic very-low-birth-weight infants receiving parenteral nutrition

Area of Science:

• Neonatology
• Endocrinology
• Pediatric Metabolism

Background:

• Hyperglycemia is a common complication in premature, very-low-birth-weight infants receiving parenteral nutrition.
• Poor glucose tolerance can impede adequate caloric intake and growth in these vulnerable infants.

Purpose of the Study:

• To evaluate the efficacy and safety of continuous insulin infusion for managing hyperglycemia in premature infants on parenteral nutrition.
• To assess the impact of insulin therapy on glucose control, caloric intake, and growth in this population.

Main Methods:

• A cohort of 30 premature infants (26.4+/-1.4 weeks gestation, 750+/-211.3 g birth weight) with hyperglycemia were treated with continuous insulin infusion.
• Insulin infusion was initiated shortly after birth, with glucose and caloric intake closely monitored.
• Enteral feeding was introduced during insulin therapy, and infant weight changes were tracked.

Main Results:

• Continuous insulin infusion rapidly restored normoglycemia within 31.4 hours in hyperglycemic infants.
• The mean maximum insulin dose required was 0.4 IU/kg/h, with a mean cumulative dose of 3.27 IU/kg.
• Insulin therapy facilitated higher non-protein caloric intake (121.7+/-16.5 kcal/kg/day) and consistent weight gain in most infants.

Conclusions:

• Continuous insulin infusion is a safe and effective method to improve glucose tolerance in very-low-birth-weight infants experiencing hyperglycemia during total parenteral nutrition.
• This intervention allows for increased caloric delivery and promotes improved growth outcomes in this high-risk infant population.